NanoBio Corporation, an Ann Arbor, Mich.-based clinical-stage biopharmaceutical company, changed its corporate name to BlueWillow Biologics and closed a $10m Series A financing.
The round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.
The company intends to use the funds to continue to advance its novel intranasal technology to develop new vaccines for several respiratory and sexually transmitted diseases.
Led by Dave Peralta, Chief Executive Officer, BlueWillow Biologics is a biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented NanoVax® technology platform. The technology employs a novel oil-in-water nanoemulsion adjuvant that is effective when administered via intranasal or intramuscular vaccination, and can elicit both mucosal and systemic immunity when applied intranasally.
The company is currently developing intranasal vaccines for several respiratory and sexually transmitted infections, including RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2 and chlamydia.